Clinical Trial

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-29
Trial Details
NCT Number NCT06516952
Lead Sponsor Incyte Corporation
Conditions Prurigo Nodularis
Enrollment 349 participants
Start Date 2024-10-10
Primary Completion 2026-10-19 (estimated)
Study Completion 2027-05-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-28